Oppenheimer Comments on Integra Lifesciences Holdings Corp’s Q1 2018 Earnings (IART)
Integra Lifesciences Holdings Corp (NASDAQ:IART) – Analysts at Oppenheimer issued their Q1 2018 EPS estimates for shares of Integra Lifesciences in a research note issued to investors on Wednesday. Oppenheimer analyst S. Lichtman expects that the life sciences company will earn $0.49 per share for the quarter. Oppenheimer has a “Buy” rating and a $60.00 price target on the stock. Oppenheimer also issued estimates for Integra Lifesciences’ Q2 2018 earnings at $0.55 EPS, Q3 2018 earnings at $0.57 EPS and Q4 2018 earnings at $0.74 EPS.
Integra Lifesciences (NASDAQ:IART) last posted its quarterly earnings results on Tuesday, February 27th. The life sciences company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.08. The business had revenue of $368.60 million during the quarter, compared to analysts’ expectations of $362.64 million. Integra Lifesciences had a net margin of 5.45% and a return on equity of 17.30%. The business’s quarterly revenue was up 44.2% on a year-over-year basis. During the same period last year, the company posted $0.52 earnings per share.
Shares of Integra Lifesciences (IART) opened at $52.70 on Thursday. The company has a quick ratio of 3.39, a current ratio of 4.49 and a debt-to-equity ratio of 1.26. The company has a market cap of $4,059.72, a price-to-earnings ratio of 26.80, a price-to-earnings-growth ratio of 1.62 and a beta of 0.65. Integra Lifesciences has a twelve month low of $40.51 and a twelve month high of $56.42.
In other Integra Lifesciences news, Director Keith Bradley sold 15,658 shares of Integra Lifesciences stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $55.00, for a total value of $861,190.00. Following the sale, the director now owns 37,074 shares of the company’s stock, valued at $2,039,070. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 21.50% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of IART. First Trust Advisors LP increased its stake in shares of Integra Lifesciences by 216.1% in the third quarter. First Trust Advisors LP now owns 51,084 shares of the life sciences company’s stock worth $2,579,000 after purchasing an additional 34,925 shares in the last quarter. Crossmark Global Holdings Inc. purchased a new position in shares of Integra Lifesciences in the third quarter worth about $619,000. Stevens Capital Management LP purchased a new position in shares of Integra Lifesciences in the third quarter worth about $647,000. Stoneridge Investment Partners LLC purchased a new position in shares of Integra Lifesciences in the third quarter worth about $572,000. Finally, Prudential Financial Inc. increased its stake in shares of Integra Lifesciences by 3.3% in the third quarter. Prudential Financial Inc. now owns 105,836 shares of the life sciences company’s stock worth $5,343,000 after purchasing an additional 3,340 shares in the last quarter. Hedge funds and other institutional investors own 86.39% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Oppenheimer Comments on Integra Lifesciences Holdings Corp’s Q1 2018 Earnings (IART)” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.dailypolitical.com/2018/03/03/oppenheimer-comments-on-integra-lifesciences-holdings-corps-q1-2018-earnings-iart.html.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.